Volume | 879,768 |
|
|||||
News | (1) | ||||||
Day High | 12.24 | Low High |
|||||
Day Low | 11.87 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Viridian Therapeutics Inc | VRDN | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
12.07 | 11.87 | 12.24 | 11.95 | 11.94 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
9,614 | 879,768 | US$ 12.00 | US$ 10,560,763 | - | 10.925 - 28.35 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
16:27:18 | 50 | US$ 12.36 | USD |
Viridian Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
750.07M | 62.77M | - | 314k | -237.73M | -3.79 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Viridian Therapeutics News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VRDN Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 12.25 | 12.615 | 11.83 | 12.07 | 813,230 | 0.11 | 0.90% |
1 Month | 15.08 | 15.76 | 11.78 | 13.58 | 891,564 | -2.72 | -18.04% |
3 Months | 19.77 | 20.23 | 11.78 | 15.44 | 915,082 | -7.41 | -37.48% |
6 Months | 16.78 | 24.18 | 11.78 | 17.89 | 933,206 | -4.42 | -26.34% |
1 Year | 24.00 | 28.35 | 10.925 | 18.08 | 842,590 | -11.64 | -48.50% |
3 Years | 17.82 | 39.00 | 9.47 | 20.25 | 533,115 | -5.46 | -30.64% |
5 Years | 21.39 | 39.00 | 9.47 | 20.23 | 478,965 | -9.03 | -42.22% |
Viridian Therapeutics Description
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease. |